The Uromigos Live & Unplugged 2023
Thank you all for following along with The Uromigos Live & Unplugged 2023, which took place November 3-4, in Nashville.
This meeting is the second annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.
Stay tuned for extensive coverage from the meeting, and check out videos from the live event, as well as follow GU Oncology Now on X for highlights from the meeting.
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
The panel discussed the latest updates in NMIBC, including relevant data pertaining to pembro, atezo, and more.
The panel discussed the latest data and updates in frontline bladder cancer during a livestreamed session.
Drs. Dorff and Agarwal share how crucial it is for mPC patients around the world to undergo germline or somatic testing.
Drs. Hope and Agarwal provide an overview of the SOC for 1L mCRPC prior to TALAPRO-2 and how the SOC has since changed.
Drs. Dorff and Agarwal summarize the toxicities associated with talazoparib for patients with metastatic CRPC.
Drs. Dorff and Agarwal discuss the goals of the TALAPRO-2 study and further understandings that subset analyses provided.
Drs. Powles and Nizam discuss her strategy of intensifying treatment upfront in oligometastatic urothelial carcinoma.
Drs. Powles, Tawagi, and Berg highlight attempts to define 2L SOC options, as well IO rechallenging in bladder cancer.
Drs. Rini, Barata, and Hamid discuss takeaways from the session, including trial design and unmet needs in the field.
Dr. Pedro Barata discusses his thoughts on the use of cisplatin in patients with bladder cancer, as well as CheckMate 901.
Dr. Vadim Koshkin gives his thoughts on the CheckMate 901 study and its data that were presented at the conference.
Dr. Petros Grivas discusses new bladder cancer data, including the TAR-200 delivery system and the SunRISe trials.
Patient advocate Mary Beth Ballard discusses how new research and data gives hope to patients with bladder cancer.
Dr. Gautam Jayram discusses his biggest takeaways from the event, including panels on non-muscle invasive bladder cancer.
Amanda Nizam, MD, discusses her proposed trial examining EV and pembrolizumab in patients with oligometastatic UC.
Dr. Regina Barragán-Carrillo discusses new data in the IO-refractory RCC setting that were presented during the RCC panel.
Scott Haake, MD, PhD, discusses his favorite frontline ccRCC data that were presented at Uromigos Live.
Benjamin Garmezy, MD, discusses what the best treatment strategies may be for RCC and the potential of IO-only strategies.
Dr. Karine Tawagi discusses her proposed trial on a phase 2 multi-arm parallel trial for metastatic UC.
Michael Morris, MD, discusses radioligand therapy for prostate cancer, including common practices and new data.
Dr. Monty Pal discusses the current IO-refractory RCC space and approaches to patients in the 2nd- and 3rd-line settings.
Dr. O'Donnell shares his impression of the data at ESMO and offers a positive outlook on the future of UC.
Dr. Beckermann shares why there is a need to identify a biomarker for patients with RCC who will benefit from belzutifan.
Dr. Saliby shares what she has liked about the RCC panels and how she sees space for new biomarkers and mechanisms of action.
Dr. Hedyeh Ebrahimi of City of Hope describes her favorite presentations and discussions related to renal cell carcinoma.
Dr. Stephanie Berg describes her presentation given on second-line treatment for mUC during the Rising Stars panel.
Dr. Park shares why it is too soon to tell if there is survival benefit to gain from Lu-177 PSMA-617 prior to chemotherapy.
Dr. Hamid describes how PSMAfore impacts treatment sequencing in mCRPC and how future trials can strengthen control arms.
Dr. Alan Tan compares the PSMAfore and VISION studies and comments on the controversy regarding OS benefit in the former.
In the final round of The Uromigos Cup, Team Cleveland battled Team LA to determine who would take home the coveted trophy.
The second round of The Uromigos Cup featured Team Cleveland versus Team NYC to see who would move on to the final round.
The first round of The Uromigos Cup featured Team Boston versus Team LA in genitourinary oncology-based trivia.
Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more.
Brian is joined by Drs. Agarwal, Dorff, McKay, and Morris to review the state of radioligand therapy.
Brian Rini, MD, asks Sam Chang, MD, and Sia Daneshmand, MD, about their takeaways from the session on NMIBC.
Dr. Terence Friedlander provides his take on CheckMate 901 and the enfortumab vedotin/pembrolizumab combination.
Tom is joined by Drs. Chang, Daneshmand, and Grivas to discuss new therapies in NMIBC and BCG-refractory NMIBC.
The second annual Uromigos: Live & Unplugged event took place in Nashville, Tennessee, on November 3-4.
Drs. McKay, Gupta, and more talk about the best moments from last year's Uromigos Live & Unplugged event.
Dr. Morris talks about potential topics to be discussed at the event, such as the PSMAfore trial and data from ESMO.
Dr. Michael Atkins discusses long-term results of IO/TKI combinations for metastatic RCC and how they may influence debate.
Dr. David McDermott from Beth Israel Deaconess Medical Center discusses his favorite Uromigos guests and episodes.
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.
Advertisement
Advertisement
